Diurnal Variation in the Pharmacokinetics and Myelotoxicity of Mercaptopurine in Children With Acute Lymphocytic Leukemia FREE

Gideon Koren, MD; Anne Marie Langevin, MD; Nancy Olivieri, MD; Ester Giesbrecht, MSc; Alvin Zipursky, MD; Mark Greenberg, MD

[+] Author Affiliations

Accepted for publication January 20, 1990.

Reprint requests to Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1×8 (Dr Koren).

Am J Dis Child. 1990;144(10):1135-1137. doi:10.1001/archpedi.1990.02150340081028.

Text Size: A A A

Published online

Article

References

Comments

ABSTRACT

ABSTRACT | REFERENCES

• During their maintenance therapy, children with acute lymphoblastic leukemia are treated with a daily dose of mercaptopurine for several years. A recent retrospective analysis has suggested that administration of the drug in the evening results in a better prognosis. We compared the disposition pharmacokinetics of mercaptopurine administered in the morning vs in the evening in 13 children with acute lymphoblastic leukemia. Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 ±142 minutes vs 176 ± 22 minutes, mean ± SEM). The area under the concentration-time curve (AUC_0-∞) was significantly larger in the evening (24713±3536 ng/mL per minute vs 17120±1474 ng/mL per minute). These differences were even more pronounced when comparing the area under the curve of the postdistributive phase (AUC^{300 mln.−∝} 7724 ± 2955 ng/mL per minute in the evening vs 2597 ± 712 ng/mL per minute during the day). In a second study, 12 children with acute lymphoblastic leukemia receiving mercaptopurine in the morning had their medication administration switched to the evening. Within 2 weeks there was a sharp fall in peripheral white blood cell counts in all patients (from 4.1 10⁹/L to 2.2 - 10⁹/L) mainly due to a drop in polymorphonuclear lymphocytes (from 2.78×10⁹/L to 1.05×10⁹/L). We conclude that the diurnal variations of mercaptopurine disposition result in clinically important myelotoxicity of the drug.

(AJDC. 1990;144:1135-1137)

REFERENCES

ABSTRACT | REFERENCES

Poplack DG. Acute lymphoblastic leukemia in childhood . In: Altman AJ, ed. Pediatr Clin North Am . 1985;;32:669-698.

Evans WE, CromWR, AbramowitchM, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia: identification of a relation between concentration and effect . N Engl J Med . 1986;;314:471-476.

Peeters M, Koren G, Jakubovic ZD, Zipursky A. Physician compliance and relapse rates of acute lymphoblastic leukemia in children . Clin Pharmacol Ther . 1988;;43:228-232.

Zimm S, Collins J, Roccardi R, et al. Variable bioavailability of oral mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med . 1983;;308:1005-1009.

Sulh H, Koren G, Whalen C, Soldin S, Zipursky A, Greenberg M. Pharmacokinetic determinants of 6MP myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia . Clin Pharmacol Ther . 1986;;40:604-609.

Rivard GE, Hoyoux C, Infante-Rivard C, Champagne J. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: better in the evening . Lancet . 1985;;2:1264-1266.

St Pierre MV, Spino M, Isles AF, Tesoro A, MacLeod SM. Temporal variation in the deposition of theophylline and its metabolites . Clin Pharmacol Ther . 1985;;38:89-95.

Smith RB, Kroboth PD, Phillips P. Temporal variations in triazalam pharmacokinetics and Pharmacodynamics after oral administration . J Clin Pharmacol . 1986;;26:120-124.

Whalen CE, Tamary H, Greenberg M, Zipursky A, Soldin SJ. Analysis of 6-mercaptopurine in serum or plasma using high performance liquid chromatography . Ther Drug Monit . 1985;;7:315-320.

D'Angenio DZ, Schumitzky A. A program package for simulation and parameter estimation in pharmacokinetic systems . Comp Prog Biomed . 1979;;9:115-134.

Zimm S, Collins JM, O'Neill D, Chabner BA, Poplock DG. Inhibition of first pass metabolism in cancer chemotherapy: interaction with 6-mercaptopurine and allopurinol . Clin Pharmacol Ther . 1983;;34:810-817.

Channer KS, Dent K, Roberts CJC. The effect of posture at the time of administration of the central depressant effects of a new hypnotic zopiclone . Br J Clin Pharmacol . 1984;;18:879-886.

Schmigelow K, Pulczynska MK, Seip M. White cell count during maintenance chemotherapy for standard-risk childhood acute lymphoblastic leukemia: relation to relapse rate . Am J Pediatr Hematol Oncol . 1988;;5:259-267.

Snodgrass W, Smith S, Trueworthy R. Pediatric clinical pharmacology of 6-mercaptopurine: lack of compliance as a factor in leukemia relapse . Proc Am Soc Clin Oncol . 1989;;3:204. Abstract.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal